anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a kind of red rice health promoting wine and preparation method thereof, it is with red rice, Semen Coiciss, Ganoderma, Hericium erinaceus (Bull. Ex Fr.) Pers., termitomycess, Armeniaca mume Sieb. as raw material, Ganoderma, Hericium erinaceus (Bull. Ex Fr.) Pers., termitomycess are pulverized respectively, soaked to obtain Ganoderma wine base and mushroom wine base, then by red rice, the common steamed rice of Semen Coiciss, after fermented again plus green plum powder continue the red rice wine base that ferments to obtain, finally by Ganoderma wine base, mushroom wine base and red rice wine base blended, heating finished product.Gained red rice health promoting wine sweet and sour taste of the present invention, has functions that appetizing promotees food, spleen invigorating is promoted the production of body fluid, and the intestines and stomach will not be caused stimulate, and can eat as aperitif with fruit juice allotment, will deeply be liked by consumer.
This is a prospective, single institution, survey-based study to assess OOP costs, financial toxicity and pateint reported outcomes (PROs') (including QOL, quality of care, and attitudes/perspectives on the role of cost in treatment decisions). Potential participants are new patient consults in Radiation Oncology Head and Neck Cancer Clinic. Patients with an indication for definitive treatment involving radiation therapy will be approached by study staff and, if amenable, enrolled in the study. After signing informed consent, they will complete a baseline survey assessing socioeconomic household information, baseline symptoms/QOL and baseline costs/financial toxicity. They will be followed prospectively and re-surveyed at 3 and 6 months after completion of radiation therapy. Repeat assessments will document treatment costs and PRO including QOL, financial toxicity, and self-reported quality of care. Patients will be asked to collect all treatment-related bills in a provided binder, which will be reviewed at each survey date. Basic demographic data (including age, sex, race, marital status, zip code, and insurance coverage), comorbidities, smoking status, cancer characteristics (stage, site, histology), treatments received, emergency department visits and hospitalization rates at baseline, end of treatment, 3 months and 6 months after radiation treatment will be collected as part of this study. Disease status and survival will also be assessed from standard of care follow-up visits up to five years after completion of radiation treatment.
The research was planned in a mixed design with a qualitative dimension in terms of determining the experimental and training needs, using the focus group interview method in the evaluation of the program, with the aim of examining the effect of pressure injury prevention training given with the blended learning approach on the care behaviors of intensive care nurses.The universe of the study consists of a total of 100 nurses working in the 3rd Level intensive care units of Istanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine. The sample size of the study was calculated by using power analysis. Since the differences between the experimental and control groups before and after the experiment were examined comparatively in the research, ANOVA will be made for mixed measurements. Accordingly, the sample size was calculated by keeping the effect size (Cohen's f) 0.25, that is, at a medium level, based on the expected averages and standard deviations of the groups. G\*Power 3.1.9.4 software (Faul, Erdfelder, Lang \& Buchner, 2007) was used for the calculation. In order to make a decision with 95% confidence for Type I, the expected power of α error was 0.05 and for Type II error 1-β expected power was 0.80. When the number of groups was entered as 2 (experiment, control), the number of measurements was 2 (pretest, posttest), the expected correlation between repeated measurements was 0.5, and the ε correction was 1, the expected total sample size for this study was calculated as 34 people. Accordingly, there will be a total of 44 people in the research, 17 people in the experimental and control groups, taking into account the possibility of data loss. In order to prevent interaction between the groups in the formation of the experimental and control groups, it will be randomly assigned by paying attention to the fact that the experimental group is from one unit and the control group is from the other unit. Homogenization will be achieved between the groups in terms of having an intensive care nursing certificate, age, years of experience, years of working in intensive care, and Knowledge Evaluation Scale score in Preventing Pressure Ulcers. It will be collected by the researcher and the nurse in charge of the unit by using the Nurse Information Form, the Information Evaluation Scale in Pressure Ulcer Prevention, the Pressure Injury Prevention Efficiency Evaluation Form, the Training Program Evaluation Form, the Semi-Structured Interview Form before the Training Program, and the Semi-Structured Interview Form after the Training Program.
The patient is a 76-year-old man. His chief complaint of chest pain led to a diagnosis of pericardial effusion of unknown cause, and pericardial drainage was performed. On the 30th day, chest pain appeared again. Echocardiography revealed a pericardial fluid reaccumulation and a substantial mass in the pericardial space. Surgical drainage was performed to find the cause. A hematoma/mass was present on the epicardium. The pericardial sac was filled with hematoma. The hematoma was removed, but part of the mass infiltrated close to the anterior descending branch of the left coronary artery, and removal of that part was abandoned. The intrapericardial hematoma and epicardium were submitted to pathology leading to the diagnosis of synovial sarcoma. The patient was discharged home 14 days after surgery.
Doxorubicin hydrochloride can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy with doxorubicin hydrochloride is generally proportional to the cumulative exposure. Include prior use of other anthracyclines or anthracenediones in calculations of cumulative dose. The risk of cardiomyopathy may be increased at lower cumulative doses in patients with prior mediastinal irradiation.

In a clinical study in 250 patients with advanced cancer who were treated with doxorubicin hydrochloride liposome injection, the risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m2 to 550 mg/m2. Cardiomyopathy was defined as >20% decrease in resting left ventricular ejection fraction (LVEF) from baseline where LVEF remained in the normal range or a >10% decrease in LVEF from baseline where LVEF was less than the institutional lower limit of normal. Two percent of patients developed signs and symptoms of congestive heart failure without documented evidence of cardiomyopathy.

Assess left ventricular cardiac function (e.g. MUGA or echocardiogram) prior to initiation of doxorubicin hydrochloride liposome injection, during treatment to detect acute changes, and after treatment to detect delayed cardiomyopathy. Administer doxorubicin hydrochloride liposome injection to patients with a history of cardiovascular disease only when the potential benefit of treatment outweighs the risk.
The invention relates to a preparation of a manganese-zinc-selenium supplement. The manganese-zinc-selenium supplement can be prepared into granules, a beverage, an oral liquid, an injection, tablets, capsules, soft capsules and a trace element additive. The invention also aims to provide a production process for use in a preparation method of a manganese-zinc-selenium supplement beverage. The beverage comprises 0.1-9mg of soluble manganese (organic manganese: manganese gluconate and the like; inorganic: manganese sulfate and the like), 0.5-25mg of soluble zinc (inorganic zinc: zinc sulfate and the like; or organic zinc: zinc gluconate and the like), 1-200mg of selenium (inorganic selenium: sodium selenite and the like; organic selenium: selenium carrageenan and the like). By using the preparation, various diseases due to general lack of manganese, zinc and selenium of the Chinese are treated, and the physical fitness of the Chinese is enhanced remarkably. The body is strengthened during water drinking, and diseases are prevented and treated.
OBJECTIVES: Aggressive driving behavior is a significant predictor of traffic accidents. In particular, the driving behavior of taxi drivers is a critical issue that can impact the safety of both drivers and passengers. This study explored the sleep, cognitive, and psychological factors associated with taxi drivers' aggressive driving behavior.
METHODS: In this descriptive study, a self-report questionnaire was distributed to taxi drivers in Seoul and Gyeonggi Province from August 22, 2022 to December 30, 2022. In all, 992 respondents were analyzed using negative binomial regression.
RESULTS: The mean score for aggressive driving behavior among taxi drivers was 13.76±11.47, with sub-scores of 3.46±3.48 for lapse, 3.31±3.16 for error, and 6.99±5.76 for violation. Contributing factors included sleep disorders, cognitive decline, and psychological factors. A higher score for aggressive driving behavior was associated with an increased severity of insomnia and daytime sleepiness, higher rates of cognitive failure, and elevated levels of depression and stress.
CONCLUSIONS: Our findings highlight the importance of addressing the sleep, cognitive, and psychological factors associated with aggressive driving behaviors among taxi drivers. Further study is needed to evaluate the causal relationship. In addition, it is imperative to develop educational programs and interventions to manage these issues effectively.
The trial will include two experimental groups. The study design will be two groups pretest-posttest design. The study will recruit patients with HNC receiving radiation or chemotherapy. The study will be conducted in Tertiary care teaching hospital, in the departments of Radiotherapy and physiotherapy of Maharishi Markandeshwar Hospital, Maharishi Markandeshwar Deemed to be University, Mullana, Ambala. Total of 48 patients will be recruited in the study. Patients will be randomized by block randomization method into two groups. One group will receive Photobiomodulation therapy whereas another group will receive Sonophoresis. Mandibular mobilization and stabilization exercises will be given to both groups. The intervention will be given for 4 weeks. Three sessions of photobiomodulation therapy will be given per week on alternating days for 12 minutes, whereas three sessions of sonophoresis will also be given per week on alternating days for 8 minutes. Mandibular mobilization, as well as stabilization exercises, will be advised to perform regularly continuously for 4 weeks. There will be blinding of patients who will receive the therapy, therapist who will administer the therapy, and therapist who will assess the patients, therefore, the study will follow triple blinding.Algometer for pain measurement, Digital vernier caliper for measuring mandibular mobility and Core measure Questionnaire-C30 (QLQ-C30) for measuring the quality of life in patients with head and neck cancer will be taken as outcome measures. The outcomes will be taken before giving intervention, then again after 2 weeks of interventions and again on another 2 weeks of intervention.
Polymeric devices for controlled release of an active agent of interest are provided. The active agent is provided within a biodegradable polymer system to supply a polymeric device for controlled release of the active agent. The polymer system is a copolymer or a polymer blend comprising a hydrophobic component and a hydrophilic component, and the polymer system does not form a hydrogel when contacted with, or immersed in an aqueous system, for example when the device is implanted in a subject. When the device is administered to a subject, for example, when it is implanted, the device releases the active agent in a controlled fashion without a lag period, or with a minimal lag period. Methods for producing the polymeric devices are also provided, as are methods of using the polymeric devices to provide for controlled release of an active agent in a subject. Preferred hydrophobic component is a PLG. Preferred hydrophilic Components are a PEG or a methoxyPEG. Preferred peptides are LHRH, goserelin, leuprolide.
UNLABELLED: 1.
OBJECTIVE: To perform a network meta-analysis to specify the route of administration that maximises the effectiveness of each of the available prophylactic uterotonics without increasing the risk for side effects. 2.
DATA SOURCES: Literature searches on 12th September 2022 included: CENTRAL, MEDLINE, Embase, CINAHL, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. The reference lists of the retrieved study records were also searched. 3.
STUDY ELIGIBILITY CRITERIA: Population: Randomized controlled trials involving women in the third stage of labour after a vaginal or caesarean delivery in hospital or community settings.
INTERVENTIONS: Systemically administered prophylactic uterotonics of any route and dose for primary postpartum hemorrhage prevention. Comparison: Any other prophylactic uterotonic, or a different route or dose of a given uterotonic, or placebo, or no treatment. Outcomes (primary): postpartum hemorrhage ≥ 500 mL and ≥ 1000 mL. 4.
STUDY APPRAISAL AND SYNTHESIS METHODS: Risk of bias and trustworthiness assessments were performed, according to Cochrane's guidance. Direct, indirect and network meta-analyses were conducted, and results were summarized either as risk ratio or mean difference with 95% confidence intervals for dichotomous and continuous outcomes, respectively. The certainty of generated evidence was assessed according to the GRADE approach. Cumulative probabilities were calculated and the surface under the cumulative ranking curve was used to create a ranking of the available drugs. 5.
RESULTS: One hundred eighty-one studies involving 122,867 randomised women were included. Most studies were conducted in hospital settings in lower-middle income countries and involved women delivering vaginally. When compared with intramuscular oxytocin, carbetocin (RR 0.58, 95 % CI 0.40-0.84) and oxytocin (RR 0.75, 95 % CI 0.59-0.97) by an intravenous bolus, and intramuscular ergometrine plus oxytocin combination (RR 0.71, 95 % CI 0.56-0.91) are probably more effective in preventing primary postpartum hemorrhage. Intramuscularly administered oxytocin and carbetocin by an intravenous bolus have a favourable side effects profile. 6.
CONCLUSIONS: Generated evidence was generally moderate and global inconsistency was low. Carbetocin and oxytocin by an intravenous bolus, and intramuscular ergometrine plus oxytocin combination are probably the top uterotonics for primary postpartum hemorrhage prevention. Large scale studies exploring different routes of administration for available prophylactic uterotonics, and women's views should be conducted.
Congenital heart disease is one of the most common congenital malformations and thus represents a considerable public health burden. Hence, the identification of individuals and families with an increased genetic predisposition to congenital heart disease (CHD) and its possible prevention is important. Even though CHD is associated with the lack of folate during early pregnancy, the genetic background of folate and methionine metabolism perturbations and their influence on CHD risk is not clear. While some genes, such as those coding for cytosolic enzymes of folate/methionine cycles, have been extensively studied, genetic studies of folate transporters (de)glutamation enzymes and mitochondrial enzymes of the folate cycle are lacking. Among genes coding for cytoplasmic enzymes of the folate cycle, MTHFR, MTHFD1, MTR, and MTRR have the strongest association with CHD, while among genes for enzymes of the methionine cycle BHMT and BHMT2 are the most prominent. Among mitochondrial folate cycle enzymes, MTHFD2 plays the most important role in CHD formation, while FPGS was identified as important in the group of (de)glutamation enzymes. Among transporters, the strongest association with CHD was demonstrated for SLC19A1.
FIELD: virology; veterinary medicine. SUBSTANCE: immunoglobulin is produced from equine serum taken from horses hyperimmunized with cultural strains of Hercules 29 parvovirus, Ada 15 adenovirus (type 2), and EMP distemper virus. The immunization procedure is as follows: first intramuscular injection in the neck and croup area 10-100 cu. cm of each antigen, second injection by the seventh day in the neck and knee lymph nodes area 30-90 cu. cm of each antigen, and the third and fourth injections intravenously by the 22nd and 37th day respectively 80-120 cu. cm of each antigen. Blood from each group of the horses is taken by the 44th day, and the sera are separated, sterilized and mixed together in equal volumes. The mixture is exposed to PEG-6000D, and the sediment is cascade-filtered through nitrocellulose filters (pore diameter 0.22-1.20 mc). EFFECT: higher immunoglobulin activity.
This intervention lasted for 8 weeks, two times each week, for 30-60 minutes of low-high intensity exercise. The content of the experimental group and control group of exercises mainly includes warm-up, primary content, and cool down. The intervention included push-ups and medicine ball exercises for the upper limbs and jumping, hopping exercises for the lower limbs. Exercises for the upper limbs were immediately followed by lower-limb exercises, with no intervening rest periods. all plyometric exercises, including those involving the upper and lower limbs, were executed with maximal effort, with the goal of reducing contact time during each repetition, and with no allowance for rest periods between jumps. During the intervention, the control group just continued with their regular training regime (e.g., normal fitness training, and injury prevention drills), twice a week, for the duration of the experiment.
Due to continuous improvements in acute medical care, the number of patients surviving severe brain damage has increased over the past decades. While some patients improve significantly during the first days after the injury, other patients remain in altered states of consciousness (i.e. coma, unresponsive wakefulness syndrome or minimally conscious state). Acquired brain damage such as cerebrovascular diseases, traumatic brain injuries or hypoxic-ischemic encephalopathies are the main causes of severe impaired consciousness.The correct classification of the level of consciousness is of great importance, since the different states of consciousness are associated with different prognoses and treatment options. Patients who show minimal signs of consciousness (MCS) a month after the onset of the disease have better chances of regaining consciousness within one year than UWS patients. Within both categories (UWS, MCS), traumatic aetiologies in turn have a better prognosis than non-traumatic aetiologies. The prognosis usually begins with the admission of the patients to the intensive care unit of the acute care facility. But even in later treatment phases, a large number of patients regain consciousness, e.g. during post-acute early rehabilitation and even years after the disease. Numerous factors are associated with the prognosis (e.g. age, aetiology, duration of illness, functional status and state of consciousness). Although there are numerous studies on the prognostic factors and outcome of patients with severe brain damage, only a few have explicitly examined patients with initially severe and long-lasting impaired consciousness. The study therefore aims to identify factors that predict the medium and long-term outcome of patients with severe impaired consciousness in early neurological rehabilitation.

Over a period of 36 months, 130 patients undergoing neurological early rehabilitation with impaired consciousness are included. It is a prospective observational study that is carried out in a single neurological rehabilitation centre (monocentric). Different routine data, disease severity and functional status are documented for each patient. In addition, MRI, EEG and evoked potentials are measured within the first week. The level of consciousness is recorded with the Coma-Recovery-Scale-Revised and serves as the primary outcome parameter. Complications, comorbidities, functional status and leve of consciousness are assessed weekly. After eight weeks, the measurement of the MRI, the EEG and the evoked potentials are repeated. After 3, 6 and 12 months, the Glasgow Outcome Scale-Revised is used to follow up the current status of the patients.
Group 2 innate lymphoid cells (ILC2s) are a type of innate immune cells that produce a large amount of IL-5 and IL-13 and two cytokines that are crucial for various processes such as allergic airway inflammation, tissue repair and tissue homeostasis. It is known that damaged epithelial-derived alarmins, such as IL-33, IL-25 and thymic stromal lymphopoietin (TSLP), are the predominant ILC2 activators that mediate the production of type 2 cytokines. In recent years, abundant studies have found that many factors can regulate ILC2 development and function. Hormones synthesized by the body's endocrine glands or cells play an important role in immune response. Notably, ILC2s express hormone receptors and their proliferation and function can be modulated by multiple hormones during allergic airway inflammation. Here, we summarize the effects of multiple hormones on ILC2-driven allergic airway inflammation and discuss the underlying mechanisms and potential therapeutic significance.
Weight-based dose (0.15 mg/kg for patients less than 38 kg, 8 mg for patients weighing 38-62 kg, or 12 mg for patients weighing greater than 62 kg) of methylnaltrexone will be administered on post-operative day 3 and again, if indicated, on post-operative day 4. This group will also receive the standard bowel protocol beginning on postoperative day one as per protocol.
Eligible subjects will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit.